Jennifer Byrne

6 days ago | healio.com | Jennifer Byrne

Key takeaways: Low-dose rifaximin plus N-acetylcysteine was superior to rifaximin alone, with significant improvements in bloating, diarrhea and pain. The combination therapy also reduced hydrogen sulfide on the breath test. SAN DIEGO — Rifaximin plus N-acetylcysteine outperformed rifaximin alone among patients with diarrhea-predominant irritable bowel syndrome, improving bloating, diarrhea and pain, according to research presented at Digestive Disease Week.

1 week ago | healio.com | Jennifer Byrne

Key takeaways: White and Hispanic women aged 65 years and older had the most pronounced increases in anal cancer incidence from 2017 to 2021. Researchers encourage a “higher index of suspicion” when evaluating these patients. SAN DIEGO — Anal cancer incidence is on the rise in the United States, with the most pronounced increases among older white and Hispanic women, according to research presented at Digestive Disease Week.

1 week ago | healio.com | Jennifer Byrne

Key takeaways: No significant differences were reported in mortality and cardiovascular outcomes between surgery and GLP-1 groups. The findings suggest GLP-1s may still improve outcomes for those who cannot undergo surgery. SAN DIEGO — Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development in patients with diabetes, obesity and metabolic dysfunction-associated steatotic liver disease.

1 week ago | healio.com | Jennifer Byrne

Key takeaways: Mutations in BRCA2, CDH1, RHOA and TP53 genes were associated with significantly worse disease-free survival and overall survival. These findings may help develop more targeted treatments. SAN DIEGO — Researchers have identified four key genes — BRCA2, CDH1, RHOA and TP53 — whose mutations appear to be associated with development and progression of gastric cancer, according to a presenter at Digestive Disease Week.

1 week ago | healio.com | Jennifer Byrne

Key takeaways:GLP-1 use appeared associated with reduced risk for various blood cancers in patients with type 2 diabetes. The mechanism behind this association remains unknown and warrants further investigation. The use of GLP-1s among patients with type 2 diabetes appeared associated with significantly reduced risk for certain hematologic malignancies compared with insulin and metformin use, according to research published in JAMA Network Open.